

# Correction

E-selectin, interleukin 18, serum amyloid A, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. *J Rheumatol* 2009;36:1371-9.

Page 1373, left column, the first paragraph should read: "Among the biomarkers evaluated at baseline in terms of correlations with select baseline clinical measures, SAA levels were significantly correlated with select clinical characteristics, including CRP ( $r = 0.656$ ,  $p < 0.001$ ), ESR ( $r = 0.270$ ,  $p < 0.001$ ), and DAS28-CRP ( $r = 0.226$ ,  $p = 0.0036$ )."

Page 1374, left column, the second section should read: "The baseline median levels of select clinical characteristics for

ACR50 responders and nonresponders were similar for CRP (1.9 and 1.6 mg/dl, respectively), ESR (42 and 36 mm/h, respectively), SJC (11 and 9, respectively), TJC (15 and 13, respectively), DAS28-CRP score (5.85 and 5.82, respectively), and DAS28-ESR score (6.76 and 6.24, respectively)." Page 1374, bottom of the left column, the sentence should read: "In the combined golimumab plus MTX group, individual reductions from baseline in MMP-9 (at Week 4) and SAA and E-selectin (both at Weeks 4 and 16) correlated significantly with improvement in DAS28-CRP at Week 16 (Table 4A)."

Table 4A should read as given below; we regret the errors. doi:10.3899/jrheum.080755C1

*Table 4A.* Correlations between percentage changes in biomarker levels and improvement in swollen and tender joint counts and DAS28-CRP at Week 16.

Biomarker	Treatment Group	Visit	Swollen Joint Count	Tender Joint Count	DAS28-CRP	DAS28-ESR
IL-18	Golimumab plus MTX	Baseline	$r = -0.178$ , $p = 0.0410$	NS	NS	NS
		Wk 4	NS	NS	NS	NA
		Wk 16	NS	NS	NS	NS
	Placebo plus MTX	Baseline	NS	NS	NS	NS
		Wk 4	NS	NS	NS	NA
		Wk 16	NS	$r = +0.465$ , $p = 0.0126$	NS	$r = -0.467$ , $p = 0.0186$
SAA	Golimumab plus MTX	Baseline	NS	NS	$r = +0.185$ , $p = 0.0335$	NS
		Wk 4	NS	NS	$r = +0.247$ , $p = 0.0057$	NA
		Wk 16	$r = -0.205$ , $p = 0.0296$	NS	$r = +0.219$ , $p = 0.0206$	$r = +0.258$ , $p = 0.0059$
	Placebo plus MTX	Baseline	NS	NS	$r = +0.417$ , $p = 0.0176$	NS
		Wk 4	NS	NS	NS	NA
		Wk 16	NS	NS	NS	NS
E-selectin	Golimumab plus MTX	Baseline	NS	NS	NS	NS
		Wk 4	$r = -0.212$ , $p = 0.0177$	$r = -0.192$ , $p = 0.0317$	$r = +0.341$ , $p = 0.0001$	NA
		Wk 16	$r = -0.216$ , $p = 0.0218$	$r = -0.230$ , $p = 0.0144$	$r = +0.306$ , $p = 0.0010$	$r = +0.301$ , $p = 0.0012$
	Placebo plus MTX	Baseline	NS	NS	NS	NS
		Wk 4	NS	NS	NS	NA
		Wk 16	NS	NS	NS	NS
CRP	Golimumab plus MTX	Baseline	NS	NS	NA	$r = +0.273$ , $p = 0.0012$
		Wk 4	NS	$r = -0.198$ , $p = 0.0240$	NA	NA
		Wk 16	$r = -0.204$ , $p = 0.0272$	NS	NA	$r = -0.257$ , $p = 0.0056$
	Placebo plus MTX	Baseline	NS	NS	NA	NS
		Wk 4	$r = -0.354$ , $p = 0.0432$	NS	NA	NA
		Wk 16	NS	NS	NA	NS
MMP-9	Golimumab plus MTX	Baseline	NS	NS	NS	NS
		Wk 4	NS	NS	$r = +0.203$ , $p = 0.0236$	NA
		Wk 16	NS	NS	NS	NS
	Placebo plus MTX	Baseline	NS	NS	NS	NS
		Wk 4	NS	NS	NS	NA
		Wk 16	NS	NS	NS	NS

CRP: C-reactive protein; DAS28-CRP/ESR: disease activity score based on 28-joint count and incorporating CRP/ESR; IL-18: interleukin-18; MMP-9: matrix metalloproteinase 9; MTX: methotrexate; NA: not applicable/invalid because DAS28-CRP includes CRP in its calculation or because DAS28-ESR was not determined at Wk 4; NS: not significant; SAA: serum amyloid A.